The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Elective breast surgery due to breast cancer
- Voluntary
- BMI ≥ 18 and ≤ 35 kg/m2
- ASA 1-3
- No regular use of beta-blockers or during the last 72 hours
- No contraindications to beta-blockers
Exclusion Criteria:
- Pregnancy or breast feeding
- AV-block, degree II or III
- Untreated cardiac insufficiency
- Sinus bradycardia, heart rate < 45 / min or symptoms
- Sick sinus syndrome
- Cardiogenic shock
- Severe peripheral vascular disorder
- Systolic blood pressure < 100 mmHg
- Long PQ-time, > 0,24 seconds
- Known hypersensitivity to beta-blockers or the ingredients of the drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Metoprolol
Metoprolol infusion
|
Intraoperative metoprolol infusion.
Other Names:
|
|
Placebo Comparator: Normal saline
Equal volume of saline.
|
Equal of volume compared to metoprolol.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anaesthesia
Time Frame: Intraoperative
|
Total consumption of desflurane
|
Intraoperative
|
|
Anaesthesia
Time Frame: Intraoperative
|
Total consumption of remifentanil
|
Intraoperative
|
|
Postoperative pain
Time Frame: First 4 postoperative hours
|
Total analgesics consumption
|
First 4 postoperative hours
|
|
Postoperative pain
Time Frame: First 4 postoperative hours
|
Time to analgesics
|
First 4 postoperative hours
|
|
Postoperative pain
Time Frame: First 4 postoperative hours
|
Numerical pain scale (0 = no pain, 10 = most pain) at rest and at movement
|
First 4 postoperative hours
|
|
Long-term pain
Time Frame: 3 months
|
The incidence and the level of pain at 3 months
|
3 months
|
|
Long-term pain
Time Frame: 1 year
|
The incidence and the level of pain at 12 months
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety and tolerability
Time Frame: Perioperative
|
Number of patients with adverse effects
|
Perioperative
|
|
Distribution to the central nervous system
Time Frame: Perioperative
|
Cerebro spinal fluid and blood samples
|
Perioperative
|
|
Life satisfaction
Time Frame: 1 year
|
Life satisfaction in a Likerts scale
|
1 year
|
|
Anxiety
Time Frame: 1 year
|
Spielberg State-Trait Anxiety Inventory
|
1 year
|
|
Depression
Time Frame: 1 year
|
Beck Depression Inventory
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Pain
- Neurologic Manifestations
- Breast Diseases
- Breast Neoplasms
- Mastodynia
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Metoprolol
Other Study ID Numbers
Other Study ID Numbers
- KUH5101090
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
NCT05020860RecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer
-
NCT02580448CompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the Breast
-
NCT01372579UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer
-
NCT00003199CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer
-
NCT01881048CompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer
-
NCT02315196Active, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer
-
NCT01222377TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
NCT01151449TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer
-
NCT01632332CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer
-
NCT07214883RecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer Awareness
Clinical Trials on Metoprolol
-
NCT07268170Enrolling by invitationCoronary Arterial Disease (CAD) | Ischemic Heart Disease (IHD)
-
NCT03488719Completed
-
NCT07519161Not yet recruitingAtrial Fibrillation
-
NCT06879769RecruitingCardiac Output | Contrast Media | Coronary Computed Tomography Angiography
-
NCT07445789Not yet recruiting
-
NCT06967194RecruitingST Segment Elevation Myocardial Infarction (STEMI) | Cardiogenic Shock Post Myocardial Infarction
-
NCT01523054CompletedAcute Myocardial Infarction
-
NCT02587351TerminatedPulmonary Disease, Chronic Obstructive
-
NCT07490067RecruitingHeart Failure With Reduced Ejection Fraction